http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004092537-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2002-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99201d2436a4eb5f6a0202bf66a8b6fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8924592d8bad3075ac495eb77069640d |
| publicationDate | 2004-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2004092537-A1 |
| titleOfInvention | Pyrrolo[2,3-d]pyrimidine and their use as purinergic receptor antagonists |
| abstract | Use of a compound of the formula (I) wherein R 1 is selected from alkyl, alkoxy, aryloxy, alkylthio, arylthio, aryl, halogen, CN, NR 7 R 8 , NR 6 COR 7 , NR 6 CO 2 R 9 and NR 6 SO 2 R 9 ; R 2 is selected from aryl attached via an unsaturated carbon; R 3 and R 4 are independently selected from H, alkyl, halogen, alkoxy, alkylthio, CN and NR 7 R 8 ; R 5 is selected from H, acyclic alkyl, COR 6 , CONR 7 R 8 , CONR 6 NR 7 R 8 , CO 2 R 9 and SO 2 R 9 ; R 6 , R 7 and R 8 are independently selected from H, alkyl and aryl or where R 7 and R 8 are in an NR 7 R 8 group R 7 and R 8 may be linked to form a hererocyclic group, or where R 6 , R 7 and R 8 are in a (CONR 6 NR 7 R 8 ) group, R 6 and R 7 may be linked to form a hererocyclic group; and R 9 is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A 2A receptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se. |
| priorityDate | 2001-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 364.